🚀 VC round data is live in beta, check it out!
Maravai LifeSciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Maravai LifeSciences and similar public comparables like Myriad Genetics, Fulgent Genetics, Indisa, Emergent BioSolutions and more.
Maravai LifeSciences Overview
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Founded
2020
HQ
Employees
570
Website
Financials (LTM)
EV
$643M
Maravai LifeSciences Financials
Maravai LifeSciences reported last 12-month revenue of $191M and negative EBITDA of ($17M).
In the same LTM period, Maravai LifeSciences generated $51M in gross profit, ($17M) in EBITDA losses, and had net loss of ($67M).
Revenue (LTM)
Maravai LifeSciences P&L
In the most recent fiscal year, Maravai LifeSciences reported revenue of $186M and EBITDA of ($31M).
Maravai LifeSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $191M | XXX | $186M | XXX | XXX | XXX |
| Gross Profit | $51M | XXX | $34M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 18% | XXX | XXX | XXX |
| EBITDA | ($17M) | XXX | ($31M) | XXX | XXX | XXX |
| EBITDA Margin | (9%) | XXX | (17%) | XXX | XXX | XXX |
| EBIT Margin | (37%) | XXX | (44%) | XXX | XXX | XXX |
| Net Profit | ($67M) | XXX | ($74M) | XXX | XXX | XXX |
| Net Margin | (35%) | XXX | (40%) | XXX | XXX | XXX |
| Net Debt | — | — | $75M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Maravai LifeSciences Stock Performance
Maravai LifeSciences has current market cap of $496M, and enterprise value of $643M.
Market Cap Evolution
Maravai LifeSciences' stock price is $3.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $643M | $496M | 0.0% | XXX | XXX | XXX | $-0.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMaravai LifeSciences Valuation Multiples
Maravai LifeSciences trades at 3.4x EV/Revenue multiple, and (37.8x) EV/EBITDA.
EV / Revenue (LTM)
Maravai LifeSciences Financial Valuation Multiples
As of April 19, 2026, Maravai LifeSciences has market cap of $496M and EV of $643M.
Equity research analysts estimate Maravai LifeSciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Maravai LifeSciences has a P/E ratio of (7.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $496M | XXX | $496M | XXX | XXX | XXX |
| EV (current) | $643M | XXX | $643M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | (37.8x) | XXX | (20.6x) | XXX | XXX | XXX |
| EV/EBIT | (9.1x) | XXX | (7.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 12.6x | XXX | 18.9x | XXX | XXX | XXX |
| P/E | (7.4x) | XXX | (6.7x) | XXX | XXX | XXX |
| EV/FCF | (12.6x) | XXX | (9.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Maravai LifeSciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Maravai LifeSciences Margins & Growth Rates
Maravai LifeSciences' revenue in the last 12 month grew by 10%.
Maravai LifeSciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
Maravai LifeSciences' rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Maravai LifeSciences' rule of X is 34% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Maravai LifeSciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | (9%) | XXX | (17%) | XXX | XXX | XXX |
| EBITDA Growth | (211%) | XXX | (152%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 87% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Maravai LifeSciences Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Maravai LifeSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Myriad Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulgent Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Indisa | XXX | XXX | XXX | XXX | XXX | XXX |
| Emergent BioSolutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Scinopharm Taiwan | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maravai LifeSciences M&A Activity
Maravai LifeSciences acquired XXX companies to date.
Last acquisition by Maravai LifeSciences was on XXXXXXXX, XXXXX. Maravai LifeSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Maravai LifeSciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMaravai LifeSciences Investment Activity
Maravai LifeSciences invested in XXX companies to date.
Maravai LifeSciences made its latest investment on XXXXXXXX, XXXXX. Maravai LifeSciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Maravai LifeSciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Maravai LifeSciences
| When was Maravai LifeSciences founded? | Maravai LifeSciences was founded in 2020. |
| Where is Maravai LifeSciences headquartered? | Maravai LifeSciences is headquartered in United States. |
| How many employees does Maravai LifeSciences have? | As of today, Maravai LifeSciences has over 570 employees. |
| Who is the CEO of Maravai LifeSciences? | Maravai LifeSciences' CEO is Bernd Brust. |
| Is Maravai LifeSciences publicly listed? | Yes, Maravai LifeSciences is a public company listed on Nasdaq. |
| What is the stock symbol of Maravai LifeSciences? | Maravai LifeSciences trades under MRVI ticker. |
| When did Maravai LifeSciences go public? | Maravai LifeSciences went public in 2020. |
| Who are competitors of Maravai LifeSciences? | Maravai LifeSciences main competitors are Myriad Genetics, Fulgent Genetics, Indisa, Emergent BioSolutions. |
| What is the current market cap of Maravai LifeSciences? | Maravai LifeSciences' current market cap is $496M. |
| What is the current revenue of Maravai LifeSciences? | Maravai LifeSciences' last 12 months revenue is $191M. |
| What is the current revenue growth of Maravai LifeSciences? | Maravai LifeSciences revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Maravai LifeSciences? | Current revenue multiple of Maravai LifeSciences is 3.4x. |
| Is Maravai LifeSciences profitable? | No, Maravai LifeSciences is not profitable. |
| What is the current EBITDA of Maravai LifeSciences? | Maravai LifeSciences has negative EBITDA and is not profitable. |
| What is Maravai LifeSciences' EBITDA margin? | Maravai LifeSciences' last 12 months EBITDA margin is (9%). |
| What is the current EV/EBITDA multiple of Maravai LifeSciences? | Current EBITDA multiple of Maravai LifeSciences is (37.8x). |
| What is the current FCF of Maravai LifeSciences? | Maravai LifeSciences' last 12 months FCF is ($51M). |
| What is Maravai LifeSciences' FCF margin? | Maravai LifeSciences' last 12 months FCF margin is (27%). |
| What is the current EV/FCF multiple of Maravai LifeSciences? | Current FCF multiple of Maravai LifeSciences is (12.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.